Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose

• DOI: 10.1042/cs20110284
• Publication Date: 2011-08-25T11:46:41Z
• Authors: Todd S. Perlstein; Robert R. Henry; Kieren J. Mather; Michael R. Rickels; Nicola I. Abate; Scott M. Grundy; Yabing Mai; Jeanine B. Albu; Jennifer B. Marks; James L. Pool; Mark A. Creager
• Keywords: Impaired fasting glucose

AngII (angiotensin II) may contribute to cardiovascular risk in obesity via adverse effects on insulin sensitivity and endothelial function. In the present study, we examined of ARB receptor blocker) therapy (losartan, 100 mg/day) function 53 subjects with stage I hypertension, abdominal impaired fasting glucose. The study design was a randomized double-blinded parallel placebo-controlled multi-centre trial 8 weeks duration. We used hyperinsulinaemic-euglycaemic clamp technique measure (expressed as 'M/I' value) RH-PAT (reactive hyperaemia-peripheral arterial tonometry) Additional measures included HOMA (homoeostasis model assessment)-B, an index pancreatic β-cell function, markers inflammation [e.g. CRP (C-reactive protein)] oxidative stress (e.g. F2-isoprostanes). did not alter [5.2 (2.7) pre-treatment 4.6 (1.6) post-treatment] compared placebo [6.1 (2.9) 5.3 post-treatment; P value significant], but improve HOMA-B (P=0.05). also change [RH-PAT, 2.15 (0.7) 2.11 1.81 (0.5) 1.76 significant]. Markers were significantly changed by therapy. conclusion, peripheral or this cohort patients essential glucose,